Lumateperone

Addressing the clinical treatment pain point of coexisting positive and negative symptoms of schizophrenia, lumateperone, as a new generation of atypical antipsychotic drug, exerts a synergistic effect through high affinity for 5-hydroxytryptamine 2A receptor, dopamine D2 receptor and 5-hydroxytryptamine transporter. While effectively controlling positive symptoms such as hallucinations and delusions, it can significantly improve negative symptoms such as affective flattening and social withdrawal, and the incidence of adverse reactions such as extrapyramidal reactions and metabolic disorders is much lower than that of traditional antipsychotic drugs. At present, this drug has been approved for the treatment of adult schizophrenia and as adjunctive therapy for adult major depressive disorder, providing a safer long-term medication option for psychiatric patients with cognitive impairment.

The global market size of lumateperone has exceeded USD 1.2 billion in 2023, with a compound annual growth rate of over 38%. The growth momentum mainly comes from the rigid clinical demand for antipsychotic drugs with low side effects. Currently, the global market is still dominated by original research manufacturers, while the Chinese market is still in the introduction stage. More than 20 pharmaceutical companies have laid out generic drug R&D. As the patent expiration date approaches, the penetration rate of domestic generic drugs is expected to rapidly increase to about 40% in the next 3 years, and the demand for upstream API will be released simultaneously. There is no publicly verifiable specific data on terminal sales in Chinese public medical institutions at present.

The original research enterprise of lumateperone is Intra-Cellular Therapies, a US-based company, with the original brand name Caplyta. Its core compound patent in the US will expire in 2026, and the compound patent in China will expire in 2027. The approved dosage form of the original product is oral tablet, with specifications of 21 mg and 42 mg. It has been included in the FDA Reference Listed Drug Catalog, and the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China has announced it as a reference preparation. As of now, no domestic lumateperone API has been approved for registration on the CDE API registration platform, and the original research API has not yet submitted DMF registration in China. A number of domestic lumateperone generic preparations are in the clinical declaration stage. (Data as of September 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of lumateperone impurity reference standards, which fully cover intermediates in the synthesis process, degradation products and process impurities. The products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA. Most products are in stock. Orders for in-stock products placed before 16:00 can be shipped on the same day, which can fully support the full-process needs of pharmaceutical companies in generic drug R&D, quality research and registration declaration.